好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cerebral Amyloid Angiopathy-related Inflammation with Atypical Imaging Features
Cerebrovascular Disease and Interventional Neurology
P5 - Poster Session 5 (11:45 AM-12:45 PM)
4-012

Describe a case of cerebral amyloid angiopathy-related inflammation (CAA-ri) without obvious radiographic features of cerebral amyloid angiopathy (CAA).

CAA-ri is a rare neuroinflammatory disease associated with beta-amyloid deposition in cerebral and leptomeningeal vessels. In addition to the Boston criteria for CAA, criteria have also been proposed for diagnosis of CAA-ri, including asymmetric white matter hyperintensities and cortical-subcortical hemorrhagic lesions. Diagnostic challenges emerge when these classic radiographic features are absent.

Case report.

A 71-year-old man with minimal prior medical history presented to the hospital with profound encephalopathy. He was found to have diffuse leptomeningeal enhancement in addition to scattered small areas of cortical diffusion restriction, without cerebral microhemorrhages or cortical superficial siderosis. A lumbar puncture was performed, which revealed an elevated opening pressure of 32 cmH2O, a total nucleated cell count of 298 cells/mcL (neutrophilic predominant), protein of 476 mg/dL, and glucose of 58 mg/dL (serum 116 mg/dL). Broad infectious and inflammatory testing was negative including metagenomic sequencing and autoimmune/paraneoplastic antibodies. He was treated with meningitis-dosed antibiotics and dexamethasone. Although he had some apparent initial clinical improvement, follow-up imaging revealed progression of diffuse leptomeningitis, new infarcts, and he developed focal seizures. Biopsy of brain and leptomeninges was pursued and ultimately revealed diffuse circumferential deposition of amyloid beta surrounding leptomeningeal and cortical vessels, colocalized with mixed inflammatory infiltrates, consistent with CAA-ri. He was treated with high-dose steroids but ultimately transitioned to comfort cares after a protracted hospitalization.

This case illustrates leptomeningeal-predominant CAA-ri in the absence of cerebral microhemorrhages or characteristic subcortical T2/FLAIR hyperintensities. CAA-ri should be considered in the differential diagnosis for patients presenting with an undifferentiated leptomeningitis, particularly in the setting of multifocal ischemic stroke, but even in the absence of other classic imaging features. Early recognition of CAA-ri is imperative given implications for treatment and patient outcomes.

Authors/Disclosures
David Sohutskay, MD, PhD
PRESENTER
An immediate family member of Dr. Sohutskay has received personal compensation for serving as an employee of Abbott. An immediate family member of Dr. Sohutskay has received personal compensation for serving as an employee of EBR Systems.
Michael Rigby, MD, PhD Dr. Rigby has nothing to disclose.
Amra Sakusic, MD Dr. Sakusic has nothing to disclose.
Sherri A. Braksick, MD, FAAN (Mayo Clinic) Dr. Braksick has nothing to disclose.
Ivan D. Carabenciov, MD (Mayo Clinic) Dr. Carabenciov has nothing to disclose.
Alejandro A. Rabinstein, MD, FAAN (Mayo Clinic) Dr. Rabinstein has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific. Dr. Rabinstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Shionogi . Dr. Rabinstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chiesi. Dr. Rabinstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ceribell. Dr. Rabinstein has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurocritical care/NCS-Springer. Dr. Rabinstein has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters/UptoDate. Dr. Rabinstein has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for EBSCO/DynaMed. Dr. Rabinstein has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AHA. Dr. Rabinstein has received publishing royalties from a publication relating to health care. Dr. Rabinstein has received publishing royalties from a publication relating to health care. Dr. Rabinstein has received publishing royalties from a publication relating to health care. Dr. Rabinstein has received publishing royalties from a publication relating to health care.
M. M. Paz Soldan, MD, PhD (Mayo Clinic) Dr. Paz Soldan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Paz Soldan has received research support from National Institutes of Health. The institution of Dr. Paz Soldan has received research support from National Multiple Sclerosis Society. The institution of Dr. Paz Soldan has received research support from Western Institute for Biomedical Research. The institution of Dr. Paz Soldan has received research support from Biogen. The institution of Dr. Paz Soldan has received research support from Novartis. The institution of Dr. Paz Soldan has received research support from Clene Nanomedicine.
Ashley Santilli, MD (Mayo Clinic) Dr. Santilli has nothing to disclose.